Ruji Yao

1.5k total citations · 1 hit paper
22 papers, 1.1k citations indexed

About

Ruji Yao is a scholar working on Rheumatology, Epidemiology and Physiology. According to data from OpenAlex, Ruji Yao has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 5 papers in Epidemiology and 5 papers in Physiology. Recurrent topics in Ruji Yao's work include Rheumatoid Arthritis Research and Therapies (6 papers), Allergic Rhinitis and Sensitization (5 papers) and Asthma and respiratory diseases (5 papers). Ruji Yao is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (6 papers), Allergic Rhinitis and Sensitization (5 papers) and Asthma and respiratory diseases (5 papers). Ruji Yao collaborates with scholars based in United States, United Kingdom and France. Ruji Yao's co-authors include Janice K. Albrecht, Stuart C. Gordon, Tobias Heintges, Mitchell L. Shiffman, Zachary Goodman, Christian Trépo, John C. Hoefs, Mark Laughlin, Eugene R. Schiff and Karen L. Lindsay and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.

In The Last Decade

Ruji Yao

21 papers receiving 1.1k citations

Hit Papers

A Randomized, Double–Blind Trial Comparing Pegylated Inte... 2001 2026 2009 2017 2001 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
    2001 507 citations Karen L. Lindsay, Christian Trépo et al. Hepatology profile →

Peers

Ruji Yao
Hiroaki Takeoka Japan
Kenichi Nishioji Japan
Maurizio Pietrogrande Italy
Adam L. Asare United States
Taofic Mounajjed United States
Christophe Legendre United States
Jos W. R. Meijer Netherlands
U. Räth Germany
G. Rossi Italy
Hiroaki Takeoka Japan
Ruji Yao
Citations per year, relative to Ruji Yao Ruji Yao (= 1×) peers Hiroaki Takeoka

Countries citing papers authored by Ruji Yao

Since Specialization
Citations

This map shows the geographic impact of Ruji Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruji Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruji Yao more than expected).

Fields of papers citing papers by Ruji Yao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruji Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruji Yao. The network helps show where Ruji Yao may publish in the future.

Co-authorship network of co-authors of Ruji Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Ruji Yao. A scholar is included among the top collaborators of Ruji Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruji Yao. Ruji Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Birring, Surinder S., Linda Cardozo, Roger R. Dmochowski, et al.. (2024). Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 12(11). 855–864. 1 indexed citations
2.
Stanislav, Marina, Anjela Tzontcheva, Ruji Yao, et al.. (2023). Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK). Lara D. Veeken. 62(11). 3601–3609. 8 indexed citations
3.
Dicpinigaitis, Peter V., Surinder S. Birring, Linda Cardozo, et al.. (2023). Patient-reported cough severity in women with chronic cough and stress urinary incontinence treated with gefapixant. PA3039–PA3039.
4.
Birring, Surinder S., Linda Cardozo, Peter V. Dicpinigaitis, et al.. (2023). Burden of disease in a phase 3b trial of gefapixant in women with chronic cough and stress urinary incontinence. PA3041–PA3041. 2 indexed citations
5.
Panés, Julián, James O. Lindsay, Niels Teich, et al.. (2019). Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy. Journal of Crohn s and Colitis. 13(9). 1148–1157. 10 indexed citations
6.
Reinisch, Walter, Jean‐Frédéric Colombel, Peter G. Gibson, et al.. (2018). Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflammatory Bowel Diseases. 25(1). 163–171. 4 indexed citations
7.
8.
Loftus, Susan, et al.. (2016). Randomized, placebo-controlled, phase III study of aprepitant in preventing chemotherapy-induced nausea and vomiting in children: Analysis by age group.. Journal of Clinical Oncology. 34(15_suppl). 10579–10579. 1 indexed citations
9.
Schulze‐Koops, Hendrik, Roberto Giacomelli, Włodzimierz Samborski, et al.. (2015). Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis.. PubMed. 33(2). 201–8. 22 indexed citations
10.
Sandborn, William J., Jean–Frédéric Colombel, Walter Reinisch, et al.. (2014). Clinical Outcomes in Continuous Clinical Responders with Moderately to Severely Active Ulcerative Colitis: Subanalyses from the PURSUIT-SC Maintenance Study. The American Journal of Gastroenterology. 109. S505–S505. 2 indexed citations
11.
Combe, Bernard, Bhaskar Dasgupta, Ingrid Louw, et al.. (2013). Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Annals of the Rheumatic Diseases. 73(8). 1477–1486. 27 indexed citations
12.
Máspero, Jorge, Vibeke Backer, Ruji Yao, Heribert Staudinger, & Ariel Teper. (2013). Effects of Mometasone, Fluticasone, and Montelukast on Bone Mineral Density in Adults with Asthma. The Journal of Allergy and Clinical Immunology In Practice. 1(6). 649–655.e1. 9 indexed citations
13.
Blaiss, Michael S., Jennifer Maloney, Hendrik Nolte, et al.. (2011). Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. Journal of Allergy and Clinical Immunology. 127(1). 64–71.e4. 194 indexed citations
14.
Day, James H., et al.. (2009). Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Annals of Allergy Asthma & Immunology. 102(4). 328–338. 15 indexed citations
15.
Horak, Friedrich, Petra Zieglmayer, René Zieglmayer, et al.. (2009). A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Annals of Allergy Asthma & Immunology. 102(2). 116–120. 36 indexed citations
16.
Prenner, Bruce M., Robert Anolik, Melvyn Danzig, & Ruji Yao. (2009). Efficacy and safety of fixed-dose loratadine/montelukast in seasonal allergic rhinitis: Effects on nasal congestion. Allergy and Asthma Proceedings. 30(3). 263–269. 8 indexed citations
17.
Day, James H., et al.. (2009). Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the Environmental Exposure Unit. Allergy and Asthma Proceedings. 30(3). 270–276. 11 indexed citations
18.
Lindsay, Karen L., Christian Trépo, Tobias Heintges, et al.. (2001). A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C. Hepatology. 34(2). 395–403. 507 indexed citations breakdown →
19.
McHutchison, John G., Thierry Poynard, Stephen Pianko, et al.. (2000). The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology. 119(5). 1317–1323. 155 indexed citations
20.
Chaudhuri, Probal, et al.. (1994). Piecewise polynomial regression trees. 1. 243–77. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroaki Takeoka Breakdown of academic impact, for papers by Kenichi Nishioji Breakdown of academic impact, for papers by Maurizio Pietrogrande Breakdown of academic impact, for papers by Adam L. Asare Breakdown of academic impact, for papers by Taofic Mounajjed Breakdown of academic impact, for papers by Christophe Legendre Breakdown of academic impact, for papers by Jos W. R. Meijer Breakdown of academic impact, for papers by U. Räth Breakdown of academic impact, for papers by G. Rossi
Rankless by CCL
2026